The Routes
How to Get Tirzepatide: The Legitimate Routes
Getting tirzepatide lawfully takes two steps. A licensed clinician evaluates you and writes a prescription. A state-licensed pharmacy fills it. Everything else is a choice about which clinician, which product and who pays.
| Route | What you receive | Who it fits | What to check |
|---|---|---|---|
| Zepbound through a retail or mail-order pharmacy | FDA-approved tirzepatide | Adults prescribed it for weight reduction or sleep apnea | Your plan's coverage and prior authorization rules |
| Zepbound self-pay through LillyDirect | FDA-approved tirzepatide, ordered through Lilly's LillyDirect service | Adults paying cash with a valid prescription | Lilly's current price and refill terms |
| Mounjaro through a pharmacy | FDA-approved tirzepatide, labeled for type 2 diabetes | Adults and children 10 and older with type 2 diabetes | Whether your plan covers it for your diagnosis |
| Compounded tirzepatide from a state-licensed pharmacy | A preparation that is not FDA-approved | A patient whose prescriber documents a medical need an approved product does not meet | Which pharmacy prepares it, and what the documented difference is |
| "Research" tirzepatide sold without a prescription | An unapproved product of unknown quality | Nobody | The FDA urges consumers not to buy it |
Protocol Health prescribes tirzepatide as part of clinician-supervised medical weight loss, so we have a commercial interest in this topic. For that reason each route below is sourced to the drug labels, the FDA and the manufacturer's own pages, all checked on October 9, 2026.
Book a medical weight loss consultZepbound vs Mounjaro
Zepbound and Mounjaro: What Tirzepatide Is Approved For
Tirzepatide is one molecule sold under two brand names, and the brand determines what it is approved to treat. Eli Lilly makes both. Both are once-weekly injections that act on the GIP and GLP-1 receptors.
The Zepbound prescribing information indicates it, in combination with a reduced-calorie diet and increased physical activity, "to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition," and "to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity."
The Mounjaro prescribing information indicates it as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high risk for them. Weight reduction is not a Mounjaro indication, so a clinician who prescribes Mounjaro for weight alone is prescribing off-label.
The Zepbound label carries one limitation of use. Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.
What the pivotal weight trial measured
The main evidence behind the weight indication is SURMOUNT-1, published in the New England Journal of Medicine in 2022 and funded by Eli Lilly. It randomized 2,539 adults to tirzepatide 5 mg, 10 mg or 15 mg weekly, or to placebo, for 72 weeks. Mean weight change was -15.0%, -19.5% and -20.9% on the three doses, against -3.1% on placebo. Those are averages. Individual results vary, and no outcome is guaranteed.
SURMOUNT-1 and the other trials in the Zepbound label tested the brand-name product. Compounded tirzepatide is not FDA-approved, is not the same as the brand-name products, and was not studied in these trials. For more on the evidence, read tirzepatide for weight loss and tirzepatide vs semaglutide.
Who Qualifies
Who Qualifies for a Tirzepatide Prescription
To qualify for tirzepatide, a person needs to fit an approved use, have no contraindication, and have a clinician judge that the benefit outweighs the risk. No online form qualifies anyone. A clinician does.
The current Zepbound label words eligibility as a diagnosis, not a number: adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition. The BMI figures people quote come from the trials the label describes. Its main weight trial enrolled adults with obesity, defined as a BMI of 30 kg/m² or more, or with overweight, defined as a BMI of 27 to under 30 kg/m², and at least one weight-related comorbid condition "such as dyslipidemia, hypertension, obstructive sleep apnea, or CV disease."
The sleep apnea indication requires moderate to severe obstructive sleep apnea in an adult with obesity. For Mounjaro, the qualifying diagnosis is type 2 diabetes. An insurer can set criteria stricter than the label, and those criteria are the plan's to state.
A clinician deciding whether to prescribe tirzepatide reviews points the label itself raises:
- Weight history and BMI, and any weight-related conditions such as hypertension, dyslipidemia or sleep apnea.
- Personal and family history of thyroid cancer, because of the boxed warning.
- Current medications. The label warns of a higher risk of hypoglycemia when tirzepatide is used with insulin or a sulfonylurea.
- History of pancreatitis, gallbladder disease or severe gastroparesis.
- Pregnancy plans and contraception.
- Planned surgery or procedures involving general anesthesia or deep sedation.
Who Should Not
Who Should Not Take Tirzepatide
Both tirzepatide labels list two contraindications. The first is a personal or family history of medullary thyroid carcinoma, or MEN 2. The second is a known serious hypersensitivity to tirzepatide or any of the product's excipients. The labels note that serious reactions, including anaphylaxis and angioedema, have been reported.
The Zepbound label addresses pregnancy directly: "Weight loss offers no benefit to a pregnant patient and may cause fetal harm." It says to discontinue Zepbound when a pregnancy is recognized. The label also states that tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying. It advises patients using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose escalation.
The label's other warnings cover severe gastrointestinal reactions, acute kidney injury from volume depletion, acute gallbladder disease, acute pancreatitis, hypoglycemia with insulin or an insulin secretagogue, diabetic retinopathy complications in patients with type 2 diabetes, and pulmonary aspiration during general anesthesia or deep sedation. It states that Zepbound is not recommended in patients with severe gastroparesis, and that its safety and effectiveness have not been established in pediatric patients.
A legitimate prescriber asks about each of these before writing a prescription. A lower dose does not remove any of them, a point our guide to microdosing tirzepatide covers in detail.
Who Prescribes
Who Can Prescribe Tirzepatide: In Person and by Telehealth
A clinician licensed to prescribe in the state where you are located can prescribe tirzepatide. That may be a primary care clinician, an endocrinologist or a weight-management practice, seen in an exam room or on video. A clinician who already knows your history can write the same prescription a weight-loss website can.
A telehealth visit leads to the same tirzepatide prescription as an office visit, and the same standards apply. The FDA's consumer page on unapproved GLP-1 drugs lists warning signs for telehealth sellers. Two of them are a company that "does not require a screening and prescription by a licensed doctor before providing medicine" and a company that "does not have a licensed doctor available to answer questions after you receive your medication."
Before you get a tirzepatide prescription online, ask the service five questions:
- Who is the prescribing clinician, and are they licensed in my state?
- Which product would the prescription be for: Zepbound, Mounjaro or a compounded preparation?
- Which pharmacy fills it, and is that pharmacy licensed in my state?
- What does the evaluation include before anything is prescribed?
- Who do I contact about side effects, and what does the full cost include?
Readers near our clinic can compare local options in medical weight loss in Westchester County and weight loss injections in Westchester.
Insurance
Is Tirzepatide Covered by Insurance?
Tirzepatide is covered by some insurance plans and not by others, and the answer belongs to your plan. Coverage turns on which brand is prescribed, which diagnosis it is prescribed for, and what the plan's formulary says this year.
Lilly's own Zepbound savings and coverage page says it plainly: "Coverage not guaranteed. Actual benefits determined by plan administrator."
A plan may require prior authorization, which means the prescriber documents why the drug is needed before the plan pays. Each plan sets what it wants documented. The steps to get tirzepatide covered by insurance are the same for any plan:
- Check the plan's formulary for Zepbound and Mounjaro by name, or call the number on your insurance card.
- Ask whether prior authorization is required and what the criteria are.
- Ask your clinician's office to submit the request with the diagnosis that matches the drug's label.
- If the request is denied, ask for the reason in writing and for the appeal process.
Two programs appeared on Lilly's page on October 9, 2026. For eligible patients whose commercial insurance covers Zepbound, Lilly advertises a Zepbound Savings Program price of as low as $25 per month for up to a 3-month prescription, with eligibility requirements and monthly and annual limits. For eligible Medicare Part D patients with a Zepbound prescription for weight management, Lilly describes access through a Medicare GLP-1 Bridge program for no more than $50 per month and states that it is not a guarantee of coverage. Lilly's terms say it may change or end its savings programs at any time.
Self-Pay
Paying Cash for Zepbound: Lilly's Self-Pay Prices
Without insurance, the first price to check is the manufacturer's. Lilly offers Zepbound to patients with a prescription through its LillyDirect service, and it publishes its self-pay prices there. For anyone looking for the lowest legitimate price, a published price for the FDA-approved product is a useful benchmark for comparing other offers.
| Zepbound strength | Self-pay price Lilly lists | Condition Lilly attaches |
|---|---|---|
| 2.5 mg (starting dosage) | Starting at $299 per month | No refill condition; Lilly's eligibility terms apply |
| 5 mg | Starting at $399 per month | No refill condition; Lilly's eligibility terms apply |
| 7.5 mg | Starting at $449 per month | When refilled within 45 days; otherwise $499 |
| 10 mg, 12.5 mg, 15 mg | Starting at $449 per month | When refilled within 45 days; otherwise $699 |
Lilly lists the same self-pay prices for the KwikPen and for single-dose vials. It describes the vials as exclusively available through LillyDirect and self-pay only, with a needle and syringe purchased separately. The KwikPen requires pen needles purchased separately. LillyDirect fills a prescription. It does not replace one.
Lilly's page repeats a line from the label: 2.5 mg is a starting dose and is not approved as a maintenance dose. Staying on the lowest-priced strength to save money is a dosing decision, and it belongs to the prescriber.
The medication price is one line of the total. Clinician visits and any lab work are billed separately by whoever provides them.
Compounded
Is Compounded Tirzepatide Still Available?
Compounded tirzepatide is still available in a narrow, patient-specific form. It is no longer permitted as a routine copy of Zepbound or Mounjaro. That is the FDA's position on its own pages, checked on October 9, 2026.
The FDA's policy page for compounders records the sequence:
- Tirzepatide injection had been in shortage since 2022.
- On December 19, 2024, the FDA determined that the tirzepatide injection shortage was resolved.
- On March 5, 2025, a federal district court denied the plaintiffs' motion for a preliminary injunction in Outsourcing Facilities Association v. FDA. The FDA then stated that its period of enforcement discretion had ended for state-licensed pharmacies and physicians compounding under section 503A.
- For outsourcing facilities under section 503B, the FDA's enforcement discretion ran until March 19, 2025.
- In its April 1, 2026 update, the FDA stated that tirzepatide and semaglutide "do not currently appear on the 503B bulks list or on FDA's drug shortage list."
What remains is ordinary section 503A compounding with its ordinary limits. A state-licensed pharmacy may compound a drug for an individual patient based on a prescription. It may not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product.
The FDA says it intends to treat a compounded drug as essentially a copy when it has the same active ingredient in the same, similar or an easily substitutable strength and can be used by the same route. The exception is a prescriber who determines and documents a change that produces a significant difference for an identified individual patient. The same update says the agency does not, at this time, intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.
The FDA's page on unapproved GLP-1 drugs, current as of October 1, 2026, gives the clinical rule: "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug." It explains that the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. As of May 31, 2026, the FDA reports more than 730 adverse event reports associated with compounded tirzepatide. It cautions that such events are likely underreported and that a report does not always establish that the drug caused the event.
If a clinic offers compounded tirzepatide, ask which state-licensed pharmacy prepares it and what documented medical need an FDA-approved product does not meet. Our guide to compounded versus brand-name GLP-1 medications covers the differences in full.
What to Avoid
Tirzepatide Without a Prescription: "Research" Vials and Other Red Flags
There is no lawful way to get tirzepatide without a prescription. A website that sells it without one is selling an unapproved drug, whatever the label says.
The FDA states that it has warned companies that illegally sold unapproved drugs containing tirzepatide "that are falsely labeled 'for research purposes' or 'not for human consumption.'" In the agency's words, these products "have been sold directly to consumers for human use with dosing instructions." The FDA "urges consumers not to purchase these products which are of unknown quality and may be harmful to their health."
The same FDA page describes fraudulent compounded tirzepatide whose labels name pharmacies that do not exist or that did not make the product.
For anyone deciding where to buy tirzepatide online, the FDA's warning signs are a seller that:
- Claims a compounded drug is the same as an FDA-approved drug.
- Offers deep discounts or prices that seem too good to be true.
- Sends medicine that looks different from what was pictured, arrives in damaged packaging or lacks instructions for use.
- Requires no screening and no prescription from a licensed clinician.
- Has no licensed clinician available to answer questions afterward.
- Ships a label with spelling errors or an incorrect pharmacy address.
The FDA also recommends that patients not use any injectable GLP-1 drug that arrives warm or without enough refrigeration. Its advice on sourcing is one sentence: "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." The agency's BeSafeRx campaign offers resources for buying prescription medicines online safely.
Over-the-counter "peptides" marketed for weight loss are a different product again. Our guide to the best peptides for weight loss explains what those products contain.
Our Approach
How Protocol Health Prescribes Tirzepatide
Protocol Health prescribes tirzepatide as one part of clinician-supervised medical weight loss, and only after an evaluation. Care is in person at one clinic, in Scarsdale, New York, and by telehealth for patients in New York, New Jersey, Connecticut, Florida and California.
Protocol Health's medical weight loss evaluation reviews your history, symptoms, goals and current medications, and the clinician may order baseline blood work. Tirzepatide is one option the clinician may discuss when it is clinically appropriate. The clinician decides whether to prescribe, which product and at what dose. This article sets no dose.
Protocol Health has a commercial interest in prescribing tirzepatide. Ask us what you would ask any clinic: whether a prescription would be for a brand-name or a compounded product, which pharmacy fills it, and what it costs. To begin, take the two-minute health quiz.
The way to get tirzepatide is to see a licensed clinician, receive a prescription if you fit an approved use and have no contraindication, and fill it at a state-licensed pharmacy as Zepbound or Mounjaro. Compounded tirzepatide is a narrow exception that needs a documented medical reason. Tirzepatide sold without a prescription is a product the FDA tells consumers not to buy. This article is educational and is not medical advice; whether tirzepatide is appropriate for you is a decision for a qualified clinician who knows your history.
FAQ
Frequently Asked Questions
Do you need a prescription for tirzepatide?
Yes. Tirzepatide is a prescription medicine sold as Zepbound and Mounjaro, and there is no over-the-counter version. The FDA has warned companies that sold tirzepatide labeled "for research purposes" directly to consumers, and it urges people not to buy those products.
Who can prescribe tirzepatide?
A clinician licensed to prescribe in the state where you are located can prescribe tirzepatide, in person or by telehealth. That may be a primary care clinician, an endocrinologist or a weight-management practice. The FDA lists a seller that requires no screening and no prescription as a warning sign.
How do you qualify for tirzepatide?
Zepbound is indicated for adults with obesity, or adults with overweight and at least one weight-related comorbid condition, and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is indicated for type 2 diabetes. A clinician also checks for contraindications before prescribing.
Is tirzepatide covered by insurance?
It depends on the plan, the brand and the diagnosis. A plan may require prior authorization, and each plan sets its own criteria. Lilly's Zepbound coverage page states that coverage is not guaranteed and that actual benefits are determined by the plan administrator.
Is compounded tirzepatide still available?
Only in a limited form. The FDA determined the tirzepatide shortage was resolved on December 19, 2024, and its enforcement discretion for 503A pharmacies ended after a March 5, 2025 court ruling. A pharmacy may still compound for an individual patient on a prescription, but may not regularly make what are essentially copies of the approved products. Compounded tirzepatide is not FDA-approved.
Can you get tirzepatide online?
Yes, through a telehealth clinician licensed in your state who evaluates you and sends a prescription to a state-licensed pharmacy. A Zepbound prescription can also be filled through Lilly's LillyDirect service. A site that ships tirzepatide with no prescription is not a legitimate route.
Explore